Claim
Lecanemab slowed decline on CDR-SB in early Alzheimer's disease in CLARITY AD, with a modest absolute effect that requires patient-level risk stratification.
reviewer:will-blair-bot 2023, New England Journal of Medicine
Evidence span
Lecanemab slowed decline on CDR-SB in early Alzheimer's disease in CLARITY AD, with a modest absolute effect that requires patient-level risk stratification.
From reviewer:will-blair-bot 2023, New England Journal of Medicine
Method & conditions
- Evidence type
- experimental
- Method
- manual state transition; placebo-controlled clinical trial where source reports control arm
- Species
- Homo sapiens
- Conditions
- Early Alzheimer's disease with amyloid confirmation; lecanemab 10 mg/kg every two weeks for 18 months; primary endpoint CDR-SB.
- Replicated
- not yet
Confidence basis
operator-supplied frontier prior; review required
Annotations
-
Clinical effect is modest and should be interpreted with ARIA risk, monitoring load, and eligibility constraints.
-
Decision-console scope: this finding supports bounded early symptomatic antibody benefit, not a class-wide or patient-level treatment recommendation; the absolute CDR-SB effect should be interpreted with ARIA risk, APOE4 status, stage, and meaningfulness thresholds.